News

USANA manufactures over 90% of its products in-house, including all of its tableted nutritional supplements. As an FDA-registered facility, USANA now has the ability to manufacture OTC drugs

With this acquisition, Hikma intends to strengthen its API sourcing and R&D capabilities in key product areas. The deal allows Hikma to get license to Haosun’s APIs particularly

Prime-A-Pump is a web-based knowledge resource and collaboration tool for building and maintaining smart-pump drug libraries. Zynx Health claims, Prime-A-Pump helps in improving the safety, quality and efficiency

The placebo controlled, randomized and single blind trial is intended to investigate the safety and efficacy o f ADXS-HPV in around three different dose cohorts. The company expects

Developed by using MonoSol Rx’s PharmFilm technology, Zuplenz is a film formulation that delivers either 4 or 8mgs of ondansetron. Zuplenz helps in preventing postoperative, highly and moderately

The agreement allows Amgen to develop and commercialize BiTE antibodies against two of the undisclosed targets which will be selected by Amgen. Amgen will be responsible to develop,

The double-blind, randomized and placebo-controlled trial showed dose-proportional pharmacokinetic exposure over the tested dose range. In the trial, the terminal half-life was approximately 20 hours. The trial investigated

The trial aims to evaluate the safety and efficacy of CRLX101 in patients with advanced NSCLC whose disease has progressed following one or two prior regimens of therapy.

Jones joined Acura in April 2008 as the senior vice president and COO and was reponsible for products development, which use the company’s proprietary abuse deterrent technologies. Acura’s